Journal Article Summary
The article investigates the effects of different synthetic progestins on the development of mammary tumors induced by DMBA (7,12-dimethylbenz[a]anthracene) in Sprague-Dawley rats. This research is significant because previous studies have shown that hormone replacement therapy, particularly combinations of estrogen and progestin, can increase breast cancer risk in post-menopausal women. Understanding how various progestins influence tumor development could help in identifying safer options for hormone therapy and cancer prevention strategies.
In the study, the researchers compared four progestins: medroxyprogesterone acetate (MPA), norgestrel (N-EL), norethindrone (N-ONE), and megestrol acetate (MGA). They found that MPA increased the incidence and reduced the time it took for tumors to develop, while N-ONE and N-EL prevented tumor formation when administered early after DMBA treatment. MGA showed little effect on tumor development. The study also revealed that N-EL could promote tumor growth if given after tumors had already formed, indicating that the timing of progestin administration is crucial.
The study has limitations, including its reliance on an animal model, which may not fully replicate human responses to progestins. Additionally, the findings suggest that while some progestins may have protective effects against early tumor development, they could potentially promote cancer progression in women with existing tumors. Patients should discuss their individual risks and the implications of hormone therapy with their healthcare providers, especially regarding family history and personal health factors that may influence breast cancer risk.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Benakanakere Indira, Besch-Williford Cynthia, Carroll Candace E., Hyder Salman M.. Synthetic progestins differentially promote or prevent DMBA-induced mammary tumors in Sprague-Dawley rats. Cancer prevention research (Philadelphia, Pa.) 2010. DOI: 10.1158/1940-6207.CAPR-10-0064. PMID: 20699413. PMCID: PMC2980323.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
